Brief: Bioporto A/S - Q3 EBIT Loss Dkk 17.7 Million

BioPorto A/S

18/11/2020 08:12

Nov 18 (Reuters) - Bioporto A/S  BIOPOR.CO :
    * REG-BIOPORTO ANNOUNCES Q3 2020 REPORT
    * REG-BIOPORTO ANNOUNCES Q3 2020 REPORT
    * BIOPORTO A/S - GUIDANCE FOR 2020 MAINTAINED
    * BIOPORTO A/S - PROVIDED CLINICAL STUDY IS COMPLETED ACCORDING TO PLAN AND EUA IS GRANTED,
CO
EXPECTS TO BE ABLE TO INITIATE COMMERCIALIZATION IN BEGINNING OF 2021
    * BIOPORTO A/S - PRODUCT SALES OF NGAL TEST GREW BY 58% YEAR-TO-DATE
    * BIOPORTO A/S - ANALYTICAL STUDIES FOR NGAL TEST™ APPLICATION ON TRACK, BUT COVID-19 SLOWS
CLINICAL ENROLLMENT
    * BIOPORTO A/S - Q3 REVENUE DKK 4.7  MILLION VERSUS DKK 6.6 MILLION YEAR AGO
    * BIOPORTO A/S - Q3 EBIT LOSS DKK 17.7 MILLION VERSUS LOSS DKK 24.0 MILLION YEAR AGO

Source text for Eikon:  ID:nGNE1CQ3sM 
Further company coverage:  BIOPOR.CO 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))